Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedImmune Studying FluMist’s Power Against Drifted Strains

Executive Summary

MedImmune is conducting studies to see if FluMist provides immunization beyond strains included in the vaccine

You may also be interested in...



Flu Vaccine Efficacy Is Too Low To “Sell,” CDC Says; Firms Want More Demand

More efficacious influenza vaccines must be developed in order to encourage use, Centers for Disease Control & Prevention Smallpox Preparedness & Response Activity Director Ray Strikas, MD, said

Flu Vaccine Efficacy Is Too Low To “Sell,” CDC Says; Firms Want More Demand

More efficacious influenza vaccines must be developed in order to encourage use, Centers for Disease Control & Prevention Smallpox Preparedness & Response Activity Director Ray Strikas, MD, said

FluMist Picks Up Insurance Reimbursement, CDC Endorsement After Outbreak

MedImmune/Wyeth's FluMist has picked up insurance company support with a series of announcements from payors that they will reimburse members receiving FluMist vaccines

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel